Several comprehensive studies showed that combining chemotherapy with COX-2 inhibitors in treating human cancers, is significantly beneficial in reducing tumor burden,32,48 while other large-scale ones found that celecoxib-combined therapy failed to improve disease-free survival or progression-free survival, and had no effect on pathological complete response.49 Here, PTGS2 is linked to neoplasm.